Sanctuary Advisors LLC Purchases New Position in DexCom, Inc. $DXCM

Sanctuary Advisors LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 44,017 shares of the medical device company’s stock, valued at approximately $2,965,000.

Several other hedge funds have also recently bought and sold shares of DXCM. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of DexCom during the second quarter worth approximately $357,000. True Freedom Investing LLC acquired a new position in shares of DexCom in the second quarter valued at approximately $3,333,000. Bank of Nova Scotia bought a new position in shares of DexCom during the second quarter worth approximately $85,284,000. Daiichi Life Insurance Co. Ltd. bought a new position in shares of DexCom during the second quarter worth approximately $892,000. Finally, Commerce Bank acquired a new stake in DexCom during the 2nd quarter worth approximately $1,422,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DXCM has been the subject of several recent research reports. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the company a “buy” rating in a research note on Monday, August 3rd. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Royal Bank Of Canada lifted their target price on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Mizuho boosted their target price on shares of DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Stock Down 2.1%

NASDAQ DXCM opened at $89.16 on Wednesday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $33.65 billion, a price-to-earnings ratio of 35.24, a PEG ratio of 1.54 and a beta of 1.41. The company has a 50 day moving average of $78.15 and a 200-day moving average of $71.19. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the prior year, the business posted $0.48 earnings per share. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. On average, equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Jon Coleman sold 4,911 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the sale, the executive vice president directly owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. This represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the transaction, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.